AUTHORS
Naveen Pemmaraju, MD, Quan Chen, PhD, MS2, Yangyang Liu, PhD3, Sima Patel, PhD4, Jalaja Potluri, MD5, Annie McNeill6, Eunice Sue Wang, MD7
AFFILIATIONS
1 MD Anderson Cancer Center, Houston, Texas, United States
2 AbbVie Inc., North Chicago, Illinois, United States
3 AbbVie Inc., North Chicago, Illinois, United States
4 AbbVie Inc., North Chicago, Illinois, United States
5 AbbVie Inc., North Chicago, Illinois, United States
6 AbbVie Inc., North Chicago, Illinois, United States
7 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
ABSTRACT
Background: BPDCN is a rare and aggressive hematologic malignancy, with an estimated incidence of 0.04 per 100,000 in the US. Recognized as a distinct myeloid neoplasm by the World Health organization (WHO) in 2016 and subsequently reclassified under dendritic cell neoplasms in 2022 (WHO 5th edition), BPDCN therapeutic options are limited with no standard treatment approaches. RW evidence is required to better characterize contemporary treatment patterns, clinical outcomes, and unmet needs in BPDCN.
Methods: This RW, retrospective, US-based study utilized the Flatiron Health electronic health record (EHR)-derived database to examine current treatment patterns and outcomes among patients diagnosed with BPDCN between January 1, 2011, and June 30, 2025. Eligible patients had BPDCN (International Classification of Diseases [ICD] system; ICD-10 code C86.4x) or evidence of structured order or administration of tagraxofusp; ≥2 documented clinical visits on different days on or after January 1, 2011; and BPDCN diagnosis confirmed by chart abstraction.
The index date was defined as the start date of systemic treatment. A line of therapy (LoT) was defined as the first eligible drug episode plus additional eligible drugs initiated within 28 days of the index date. Systemic therapies, defined by an order or administration of an antineoplastic agent recorded in the EHR, were included in LoTs. Stem-cell transplantation dates, including autologous and allogeneic transplants, were abstracted from unstructured data and incorporated into LoT. First-line therapy (1L) was defined as the first eligible therapy initiated on or up to 14 days before the index date. A new LoT was assigned when the interval between sequential drug episodes exceeded 60 days. RW outcomes included derived induction failure and relapse (dIFR; determined by presence of ≥1 of the following: bone marrow biopsy [BMBx] blasts ≥5%, documented provider assessment of BMBx was “Failure to Respond'' or “Relapse,” or peripheral blood blasts >0%), time to treatment discontinuation (rwTTD), and time to next treatment (rwTTNT), and event-free survival (rwEFS; defined as the time from treatment initiation until the patient experiences dIFR or death).
Results: The cohort included 199 patients with newly diagnosed BPDCN, with a median follow-up of 74.0 months. Of all patients, 166 (83.4%) were male and 140 (70.4%) were White, with a median (IQR) age at diagnosis of 71.0 (60.0–79.0) years. Most patients (n=121 [60.8%]) were diagnosed and/or treated in academic settings. Extramedullary disease was present in 174 (87.4%) patients at diagnosis, most commonly involving the skin (n=149 [74.9%]) and lymph nodes (n=53 [26.6%]). Among patients with biomarker data (n=186), 174 (93.5%) were CD123-positive.
Overall, 43 (21.6%) patients had prior or concomitant hematologic malignancies (PCHM). Hematopoietic stem-cell transplantation (HSCT) was performed in 60 (30.2%) patients; 53 (88.3%) underwent allogeneic transplantation and 7 (11.7%) underwent autologous transplantation, with a median (IQR) interval of 199 (153–264) days from diagnosis to HSCT. A total of 168 (84.4%) patients received ≥1 line of systemic therapy. The median (IQR) time from diagnosis to treatment initiation was 42 (19–66) days. Tagraxofusp-based regimens (n=57 [28.6%]), hyper-CVAD (n=38 [19.1%]), and venetoclax-based regimens (n=24 [12.1%]) were the most frequently used 1L therapies. In the 1L, median (95% CI) rwTTD and rwTTNT was 2.8 (2.3–3.5) and 4.8 (4.1–5.6) months, respectively. Overall, 101 (50.8%) and 49 (24.6%) patients received 2L and 3L therapies, respectively; median (IQR) time from start of previous LoT to 2L and 3L therapy was 119 (75–186) and 133 (60–271) days, respectively. Overall, 144 (85.7%) treated patients experienced a dIFR event, with a median (IQR) time to dIFR of 1.1 (0.7–1.9) months. rwEFS at 12 and 24 months were 40% and 30%, respectively. Patients with PCHM (n=33) vs those with de novo BPDCN (n=135) had inferior rwEFS (12 months: 28% vs 42%; 24 months: 9% vs 35%); of patients who received tagraxofusp-based regimens in any LoT (n=68), rwEFS at 12 and 24 months was 28% and 15%, respectively.
Conclusions: In this RW study, patients with BPDCN received heterogeneous treatment regimens and experienced poor clinical outcomes. These findings underscore the substantial unmet need for novel therapeutic strategies and standardized treatment approaches in BPDCN.
DISCLOSURES
Naveen Pemmaraju, MD: HemOnc Times/Oncology Times - Other (including travel support); Physician’s Education Resource - Honoraria; MDEducation - Honoraria; PVEK - Honoraria; Indy Hematology Education - Honoraria; Synapse Medical Communications - Honoraria; Takeda - Research Funding; Johnson & Johnson - Research Funding; US Department of Defense - Research Funding; AbbVie - Research Funding; Institutional funding from US Department of Defense - Research Funding; Meiji - Research Funding; Opna bio LLC - Research Funding; National Institutes of Health/National Cancer Institute (NIH/NCI) - Research Funding; Karyopharm Therapeutics - Research Funding; Sager Strong Foundation - Research Funding; Incyte - Research Funding; Menarini-Stemline Therapeutics - Research Funding; Disc Medicine - Research Funding; Karger Publishers - Patents & Royalties; ASH Committee on Communications - Consultancy (Includes expert testimony); Disc Medicine - Consultancy (Includes expert testimony); Dava Oncology - Consultancy (Includes expert testimony); Karyopharm Therapeutics - Consultancy (Includes expert testimony); Menarini-Stemline Therapeutics - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Patient Power - Consultancy (Includes expert testimony); Harborside Press - Consultancy (Includes expert testimony); Meiji - Consultancy (Includes expert testimony); Eli Lilly & Co - Consultancy (Includes expert testimony); Bristol-Myers Squibb - Consultancy (Includes expert testimony); Aptitude Health - Consultancy (Includes expert testimony); HemOnc Times/Oncology Times - Consultancy (Includes expert testimony); Celgene - Consultancy (Includes expert testimony); Aplastic Anemia and MDS International Federation - Consultancy (Includes expert testimony); Medscape - Consultancy (Includes expert testimony); CTI BioPharma Corporation - Consultancy (Includes expert testimony); MorphoSys - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); Menarini Group - Consultancy (Includes expert testimony); Paylex - Consultancy (Includes expert testimony); EUSA Pharma - Consultancy (Includes expert testimony); Silence Therapeutics - Consultancy (Includes expert testimony); Cimeio Therapeutics - Consultancy (Includes expert testimony); Clearview Healthcare Partners - Consultancy (Includes expert testimony); Cogent Biosciences - Consultancy (Includes expert testimony); Blueprint Medicines - Consultancy (Includes expert testimony); PharmaEssentia - Consultancy (Includes expert testimony); OncLive - Consultancy (Includes expert testimony); Intellisphere - Consultancy (Includes expert testimony); Magdalen Medical Publishing - Consultancy (Includes expert testimony); Curio Science - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); BeONe - Consultancy (Includes expert testimony); Dan's House of Hope - Consultancy (Includes expert testimony); Immunogen - Consultancy (Includes expert testimony); Opna bio LLC - Consultancy (Includes expert testimony); Pacylex - Consultancy (Includes expert testimony); Imedex - Consultancy (Includes expert testimony); Geron - Consultancy (Includes expert testimony); Astellas Pharma - Consultancy (Includes expert testimony); Cimeio Therapeutics AG - Consultancy (Includes expert testimony); Physician’s Education Resource - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); CareDx - Consultancy (Includes expert testimony); CancerNet - Consultancy (Includes expert testimony); Neopharm - Consultancy (Includes expert testimony); ASCO Cancer.Net Editorial Board - Consultancy (Includes expert testimony); PeerView Institute for Medical Education - Consultancy (Includes expert testimony); Neopharm - Consultancy (Includes expert testimony); Cimeio Therapeutics AG - Speakers Bureau.; Paylex - Speakers Bureau.; Cimeio Therapeutics AG - Membership on a Board/Advisory Committee; Paylex - Membership on a Board/Advisory Committee; Dan’s House of Hope - Membership on a Board/Advisory Committee